Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)
Danish pharma giant Novo Nordisk is under intense pressure today after its high‑profile Alzheimer’s trials for semaglutide failed, sending the stock to multi‑year lows and capping a brutal year for NVO shareholders. Novo Nordisk stock today: how far has NVO fallen? Novo Nordisk’s Alzheimer’s setback is hitting the share price hard on Monday, 24 November 2025: Despite the sell‑off, Novo Nordisk still carries a market capitalisation in the $210–215 billion range, according to multiple data providers — down sharply from its 2024 peak, but still firmly in “mega‑cap” territory. Companies Market Cap+2MacroTrends+2 For investors, today’s move is less about short‑term